Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Ginkgo Bioworks Holdings, Inc. (DNA) had Consolidated Net Income/Loss of $-82.59M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$19.47M |
|
$-82.59M |
|
$3.10M |
|
$16.38M |
|
$90.85M |
|
$-71.37M |
|
$-4.76M |
|
$-76.14M |
|
$-74.92M |
|
$-76.06M |
|
$-76.06M |
|
|
Consolidated Net Income/Loss |
$-82.59M |
$-74.84M |
|
$-71.37M |
|
$-58.58M |
|
59.56M |
|
59.56M |
|
$-1.39 |
|
$-1.39 |
|
| Balance Sheet Financials | |
$409.95M |
|
$163.02M |
|
$623.12M |
|
$1.03B |
|
$79.59M |
|
-- |
|
$510.33M |
|
$589.92M |
|
$443.15M |
|
$394.29M |
|
$443.15M |
|
61.66M |
|
| Cash Flow Statement Financials | |
$-46.69M |
|
$23.13M |
|
$-0.02M |
|
$212.37M |
|
$233.84M |
|
$21.47M |
|
$15.85M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
84.09% |
|
-366.51% |
|
-366.51% |
|
-- |
|
-390.98% |
|
-424.09% |
|
$-48.62M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
-- |
|
0.96 |
|
93.67 |
|
-17.16% |
|
-19.29% |
|
-7.36% |
|
-17.16% |
|
$7.19 |
|
$-0.82 |
|
$-0.78 |
|